Araştırma Makalesi

Tip 2 diyabet mellitusta demans biyobelirteçlerinin düzeyi

Cilt: 48 Sayı: 3 30 Eylül 2023
PDF İndir
EN TR

The level of dementia biomarkers in type 2 diabetes mellitus

Abstract

Purpose: Like Alzheimer's disease, a disease of the aging world, and metastasis in cancer, it is very important to elucidate the etiology of Type 2 diabetes, which causes tissue and organ damage by systematically spreading throughout. In this study, we aimed to examine whether markers used as biomarkers in Alzheimer's pathogenesis are effective in the pathogenesis of diabetes. Materials and Methods: In our study, 30 type 2 diabetics, 30 type 2 diabetics individuals with the risk of dementia as a result of mini-mental test, and 28 healthy individuals aged 50-70 years were included, and brain-derived neurotrophic factor (BDNF), dual-specificity tyrosine-regulated kinase 1 (DYRK1A), Tau, fatty acid binding proteins 7 (FABP7) levels were measured from plasma samples. Results: There was a significant difference between the diabetes group with a high risk of dementia (MMSE < 24) and the other groups in Tau, and FABP7 levels, but no significant differences were found in BDNF and DYRK1A levels. Conclusion: These biomarkers might be used to diagnose Alzheimer's disease in patients with T2D and at risk of dementia before resorting to other more expensive and invasive diagnostic methods.

Keywords

Diabetes Mellitus Type 2 , Alzheimer’s Disease , brain-derived neurotrophic factor , Tau protein , fatty acid- binding proteins 7 , protein serin-threonine kinases

Kaynakça

  1. Miklossy J, Qing H, Radenovic A, Kis A, Vileno B, Làszló F et al. Beta-amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging. 2010;31:1503-15.
  2. Wijesekara N, Gonçalves RA, De Felice FG, Fraser PE. Impaired peripheral glucose homeostasis and alzheimer's disease. Neuropharmacology. 2018;136:172-81.
  3. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2007;50:431-8.
  4. Rozanska O, Uruska A, Zozulinska-Ziolkiewicz D. Brain-derived neurotrophic factor and diabetes. Int J Mol Sci. 2020;21:841.
  5. Deboever E, Fistrovich A, Hulme C, Dunckley T. The Omnipresence of DYRK1A in human diseases. Int J Mol Sci. 2022;23:9355.
  6. Jaiswal S, Mishra S, Torgal SS, Shengule S. Neuroprotective effect of epalrestat mediated through oxidative stress markers, cytokines and TAU protein levels in diabetic rats. Life Sci. 2018;207:364-71.
  7. Islam A, Kagawa Y, Miyazaki H, Shil SK,Umaru BA, Yasumoto Y et al. FABP7 protects astrocytes against ROS toxicity via lipid droplet formation. Mol Neurobiol. 2019;56:5763-79.
  8. Yasumoto Y, Miyazaki H, Ogata M, Kagawa Y, Yamamoto Y, Islam A et al. Glial fatty acid-binding protein 7 (FABP7) regulates neuronal leptin sensitivity in the hypothalamic arcuate nucleus. Mol Neurobiol. 2018;55:9016-28.
  9. Güngen C, Ertan T, Eker E, Yaşar R. Standardize mini mental test’in türk toplumunda hafif demans tanısında geçerlik ve güvenilirliği. Türk Psikiyatri Dergisi. 2002;13:273-81.
  10. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.

Kaynak Göster

MLA
Özpak, Lütfiye, vd. “The level of dementia biomarkers in type 2 diabetes mellitus”. Cukurova Medical Journal, c. 48, sy 3, Eylül 2023, ss. 825-32, doi:10.17826/cumj.1311596.